Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy Biotech Investing
RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA for H. pylori Infection Pharmaceutical Investing
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa Pharmaceutical Investing
Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine Biotech Investing
Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera Microsphere Technology Pharmaceutical Investing
BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma in China Pharmaceutical Investing
Reata Announces Receipt of $30 Million Milestone Payment From Kyowa Hakko Kirin Pharmaceutical Investing
Cardiol Therapeutics Appoints Mr. Chris Waddick as Chief Financial Officer, Ms. Anne Tomalin as Director of Regulatory Affairs, and Ms. Dolly Kao as Intellectual Property Counsel Cannabis Investing News
Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss Pharmaceutical Investing
Cynata CYP-001 Stem Cell Therapy Meets All Safety and Efficacy Endpoints in Phase 1 Trial in GvHD Pharmaceutical Investing
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphylaxis Pharmaceutical Investing
